Global Novel Oral Anticoagulants (NOAC) Market Size, Share, and COVID-19 Impact Analysis, By Drug Type (Dabigatran, Rivaroxaban, Apixaban, Edoxaban, and Others), By Application (Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, and Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Novel Oral Anticoagulants (NOAC) Market Insights Forecasts to 2035

• The Global Novel Oral Anticoagulants (NOAC) Market Size Was Estimated at USD 12.80 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.68% from 2025 to 2035
• The Worldwide Novel Oral Anticoagulants (NOAC) Market Size is Expected to Reach USD 31.97 Billion by 2035
• Asia Pacific is expected to Grow the fastest during the forecast period.

According to a Research Report Published by Spherical Insights and Consulting, The Global Novel Oral Anticoagulants (NOAC) Market Size was worth around USD 12.80 Billion in 2024 and is projected to Grow from USD 13.91 Billion in 2025 to around USD 31.97 Billion by 2035 at a compound annual growth rate (CAGR) of 8.68% during the forecast period (2025–2035). The expansion of the global novel oral anticoagulants (NOAC) market is propelled by the increasing incidence of heart conditions such as pulmonary embolism, deep vein thrombosis, and atrial fibrillation, particularly in older adults. Clinical benefits over warfarin, such as predictable dosage, fewer dietary interactions, and the elimination of frequent INR monitoring, which increases patient compliance, further boost growth.

Global Novel Oral Anticoagulants (NOAC) Market Forecast and Revenue Outlook

• 2024 Market Size: USD 12.80 Billion
• 2035 Projected Market Size: USD 31.97 Billion
• CAGR (2025-2035): 8.68%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Market Overview

Novel oral anticoagulants (NOAC), often referred to as non-vitamin K antagonist oral anticoagulants, are a type of blood thinning medication used to treat and prevent blood clots. The market for novel oral anticoagulants has grown significantly over the last ten years due to rising knowledge of the advantages of anticoagulation therapy and the prevalence of thromboembolic illnesses. The NOACs, which include medications like dabigatran, apixaban, and rivaroxaban, have several benefits over warfarin and other conventional anticoagulants. They are more convenient for both patients and healthcare professionals because of these advantages, which include fewer dietary restrictions, more predictable pharmacokinetics, and no requirement for routine monitoring. Atrial fibrillation, which frequently necessitates anticoagulant medication, affects between 2 and 6 million Americans, according to the CDC, which further fuels market demand.

Governments and international health organizations have made significant progress in expanding access to novel oral anticoagulants. Notably, NOACs were recognized as important treatments for non-valvular atrial fibrillation and stroke prevention, particularly in low- and middle-income countries, and were included in the World Health Organization's Model List of Essential Medicines in 2019. Newer anticoagulants are listed on India's National List of Essential Medicines, which aids in public sector supply and procurement through initiatives like the Jan Aushadhi program, which seeks to offer high quality generic medications at reasonable costs.

Key Market Insights

• North America is expected to account for the largest share in the novel oral anticoagulants (NOAC) market during the forecast period.
• In terms of drug type, the dabigatran segment is projected to lead the novel oral anticoagulants (NOAC) market throughout the forecast period
• In terms of application, the atrial fibrillation segment captured the largest portion of the market

Novel Oral Anticoagulants (NOAC) Market Trends

• Increased Adoption of NOACs Over Traditional Therapies
• Expansion of Indications Beyond Atrial Fibrillation
• Emergence of Generic NOACs
• Technological Integration in Anticoagulation Management
• Rising Prevalence of Cardiovascular Diseases

Report Coverage

This research report categorizes the novel oral anticoagulants (NOAC) market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the novel oral anticoagulants (NOAC) market. Recent market developments and competitive strategies, such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the novel oral anticoagulants (NOAC) market.

Driving factors

The novel oral anticoagulants (NOAC) market is driven by the increasing prevalence of cardiovascular disease globally. The World Health Organization estimates that cardiovascular diseases cause 17.9 million deaths per year, which is the leading cause of death worldwide. The increased understanding of stroke prevention and the need for effective anticoagulant therapy also led to an increase in NOAC use. Both patients and healthcare providers like the rapid onset of action and steady dosing regimen. Another vital factor in the demand for NOACs is the aging population. As life expectancy increases, age related diseases such as venous thromboembolism and atrial fibrillation are becoming more prevalent. The American Geriatrics Society notes that 12% of individuals age 80 and older have atrial fibrillation, which drives a large market for anticoagulants intended for that population.

Restraining Factor

One of the main factors restraining the novel oral anticoagulants (NOAC) market is the high cost as compared to older anticoagulants like warfarin. For many healthcare insurers, there can be a challenge in the cost of possibly adopting these newer therapies into established treatment plans. Some healthcare professionals may also be more cautious and aggressive with NOACs due to concerns of a lack of antidotes for some of the medications, which can be challenging in the event of managing bleeding.

Market Segmentation 

The global novel oral anticoagulants (NOAC) market is divided into drug type and application.

Global Novel Oral Anticoagulants (NOAC) Market, By Drug Type:

• The dabigatran segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.  

Based on drug type, the global novel oral anticoagulants (NOAC) market is segmented into dabigatran, rivaroxaban, apixaban, edoxaban, and others. Among these, the dabigatran segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segment is driven as it was the first NOAC, a direct thrombin inhibitor that has become popular for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for which it is FDA approved. Both patients and providers are pleased with dabigatran due to its fixed dose and giving peace of mind because there is no need for periodic monitoring of the INR. Dabigatran retains significant market share despite the subsequent introduction of newer NOACs, as rivaroxaban, its closest competitor, and alternatives from other companies are becoming available. 

The rivaroxaban segment in the novel oral anticoagulants (NOAC) market is expected to grow at the fastest CAGR over the forecast period. Rivaroxaban is another NOAC that is an important agent, and is a direct factor Xa inhibitor that is widely used for the treatment of venous thromboembolism and for stroke prevention in patients with atrial fibrillation. Rivaroxaban is also popular due to its dosing of once a day and wide range of approved indications.

Global Novel Oral Anticoagulants (NOAC) Market, By Application:

• The atrial fibrillation segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on application, the global novel oral anticoagulants (NOAC) market is segmented into atrial fibrillation, deep vein thrombosis, pulmonary embolism, and others. Among these, the atrial fibrillation segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The dominance is due to its high rate of incidence, along with its concomitant high risk of stroke. NOACs are considered the gold standard for stroke prevention in AF patients due to their efficacy, safety, and ease of use compared to more traditional therapies such as warfarin. The demand for NOACs in this application is expected to increase alongside an ongoing increase in the global burden of AF.

The deep vein thrombosis segment in the novel oral anticoagulants (NOAC) market is expected to grow at the fastest CAGR over the forecast period. Venous thromboembolism, which includes pulmonary embolism and deep vein thrombosis, represents another important application market for NOACs. There is a need for effective preventative and treatment options due to the high rates of morbidity and mortality associated with these conditions.

Regional Segment Analysis of the Global Novel Oral Anticoagulants (NOAC) Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America Novel Oral Anticoagulants (NOAC) Market Trends

North America is expected to hold the largest share of the global novel oral anticoagulants (NOAC) market over the forecast period.

The North American region's supremacy is due to cardiovascular diseases are prevalent, and its healthcare system is very developed. Approximately 40% of the global NOAC market share in 2023 originated from North America. Major factors behind market growth include the region's ample clinical research initiatives, favorable reimbursement policies, and commitment to healthcare innovation. Many pharmaceutical companies have made sizable investments in developing and commercializing NOACs, which makes the United States a significant portion of the regional market.

Asia Pacific Novel Oral Anticoagulants (NOAC) Market Trends

Asia Pacific is expected to grow at the fastest CAGR in the novel oral anticoagulants (NOAC) market during the forecast period. In the Asia Pacific market, the rise is due to rapid growth. There has been a rise in the prevalence of atrial fibrillation and other cardiovascular diseases, along with increasing healthcare costs and easier access to advanced treatments. The economic growth and aging population in China, Japan, and India, three key markets in the region, are driving the demand for NOACs. Due to the advancement of healthcare infrastructure and government programs to improve access to healthcare, the region is the target for international pharmaceutical companies looking to broaden their footprint in multinational pharmaceutical company markets.

Europe Novel Oral Anticoagulants (NOAC) Market Trends

Europe is a significant market for NOACs due to the increasing usage of these drugs as standard anticoagulation treatments. The existing healthcare infrastructure in the region and the understanding of patients and healthcare professionals about the benefits of NOAC represent market expansion.  The market further benefits from favorable regulation and reimbursement policies in countries such as Germany, France, and the UK. As long as new clinical guidelines continue to recommend NOACs as standard therapy, the European market is anticipated to expand at a moderate rate.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global novel oral anticoagulants (NOAC) market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

Worldwide Top Key Players in The Novel Oral Anticoagulants (NOAC) Market Include

• Johnson & Johnson
• Boehringer Ingelheim
• Sanofi
• Daiichi Sankyo
• Armatheon
• Aspen
• AstraZeneca
• Bayer
• Cellceutix
• Cosmo Pharmaceuticals
• CSL Behring
• Eisai
• GSK
• Marathon Pharmaceuticals
• Ockham Biotech
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent development

• In February 2025, Novartis completed the acquisition of Anthos Therapeutics for about USD 3.10 billion to enhance its cardiovascular portfolio. The principal interest is abelacimab, a monoclonal antibody that inhibits Factor XI. Abelacimab is under Phase III trials for stroke prevention in atrial fibrillation and cancer associated thrombosis.

• In February 2021, Bayer introduced a new indication for its NOAC agent in Vietnam for patients with Peripheral Artery Disease (PAD), used in combination with aspirin to reduce major adverse cardiovascular and limb events. This came via collaboration with Bach Mai Hospital, including educational programs and clinical discussions.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the novel oral anticoagulants (NOAC) market based on the following segments:

 Global Novel Oral Anticoagulants (NOAC) Market, By Drug Type

• Dabigatran
• Rivaroxaban
• Apixaban
• Edoxaban
• Others

Global Novel Oral Anticoagulants (NOAC) Market, By Application

• Atrial Fibrillation
• Deep Vein Thrombosis
• Pulmonary Embolism
• Others

Global Novel Oral Anticoagulants (NOAC) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa